Literature DB >> 11144651

Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer.

H Matsuyama1, Y Baba, G Yamakawa, N Yamamoto, K Naito.   

Abstract

BACKGROUND: Using the percentage (of total) of free prostate-specific antigen (PSA) in discriminating prostate cancer (CaP) from benign prostate hyperplasia (BPH) has not been fully delineated in Japanese men. To clarify the clinical significance of percent free PSA, various parameters, including total prostate volume, percent free PSA, PSA density (PSAD) and PSA density of transition zone volume (PSAT), were compared.
METHODS: Ninety-seven patients who had visited one of three community-based hospitals, and whose total PSA value ranged from 4 to 20 ng/mL were prospectively enrolled in this study. Fresh sera were applied to measure the percent free PSA.
RESULTS: Of the 97 patients, CaP and BPH were diagnosed in 24 (25%) and 73 patients, respectively. In discriminating CaP patients, the cutoff values of 17% for percent free PSA, 0.3 ng/mL per cm3 for PSAT, and 0.19 ng/mL per cm3 for PSAD yielded specificity levels of 56, 40 and 58% at sensitivity levels of 92, 92 and 79%, respectively. As for the 65 patients with intermediate PSA, range 410 ng/mL, and normal digital rectal examination, the percent free PSA and total prostate volume statistically discriminated CaP patients from BPH patients. A multiple logistic regression model proved percent free PSA to be the only significant discriminating factor (P=0.045; odds ratio, 9.06).
CONCLUSIONS: This prospective study revealed percent free PSA to be a significant useful predictor in discriminating CaP from BPH in Japanese men.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144651     DOI: 10.1046/j.1442-2042.2000.00221.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

1.  Serum PSA levels in the Indian population: Is it different?

Authors:  Amit Agrawal; Shailesh Chandra Karan
Journal:  Med J Armed Forces India       Date:  2016-11-30

2.  Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.

Authors:  Li-Bin Nan; Xiao-Tao Yin; Jiang-Ping Gao
Journal:  Med Sci Monit       Date:  2019-11-06

3.  The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0-10.0 ng/mL) in Nigeria.

Authors:  E V Ezenwa; K H Tijani; E A Jeje; O O Soriyan; M A Ogunjimi; R W Ojewola; O I Ajie; A R El-Nahas
Journal:  Arab J Urol       Date:  2012-07-12

Review 4.  Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).

Authors:  Zhonglin Cai; Haidi Lv; Wenjuan Cao; Chuan Zhou; Qiangzhao Liu; Hui Li; Fenghai Zhou
Journal:  Mol Med Rep       Date:  2017-09-13       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.